



Keywords

Transfer RNA,
In vitro tRNA Binding,
Circular Dichroism,
Thermal Denaturation,
Fluorescence Spectroscopy

Received: April 1, 2015

Revised: May 14, 2015

Accepted: May 16, 2015

Insights into Evaluation of Copper Based Drug as Chemotherapeutic Agent that Target tRNA: Spectroscopic, Biological and Molecular Docking Studies

Waddhaah M. Al-Asbahy^{1,*}, Manal Shamsi¹,
Niyazi A. S. Al-Areqi¹, Gamal Al-amery²

¹Department of Chemistry, Taiz University, Taiz, Yemen

²Department of Microbiology, Taiz University, Taiz, Yemen

Email address

wadahm2007@yahoo.com (W. M. Al-Asbahy)

Citation

Waddhaah M. Al-Asbahy, Manal Shamsi, Niyazi A. S. Al-Areqi, Gamal Al-amery. Insights into Evaluation of Copper Based Drug as Chemotherapeutic Agent that Target tRNA: Spectroscopic, Biological and Molecular Docking Studies. *International Journal of Chemical and Biomedical Science*. Vol. 1, No. 5, 2015, pp. 119–129.

Abstract

Interaction of new dinuclear copper (II) complex 1, $[\text{Cu}_2(\text{glygly})_2(\text{ppz})(\text{H}_2\text{O})_4] \cdot 2\text{H}_2\text{O}$, derived from dipeptide (glycyl glycine anion) and piperazine as a metalloprotein drug with tRNA was examined by UV-visible, Fourier transform-infrared (FT-IR), and fluorescence spectroscopy, circular dichroism (CD), and isothermal titration calorimetry (ITC). The binding constants (K_b), and binding site number (n), and corresponding thermodynamic parameters; ΔG , ΔH and ΔS were calculated. ITC results showed that the complex 1 binds strongly with tRNA ($K_b \sim 4.504 \times 10^4 \text{M}^{-1}$). The distance between tRNA (donor) and complex 1 (acceptor) was estimated by means of fluorescence resonance energy transfer (FRET). The molecular docking technique utilized for ascertaining the mechanism and mode of action towards the molecular target tRNA indicated that complex 1 has a strong binding affinity to tRNA. Moreover, the growth inhibitory effects of the complex 1 on the sw480 cancer cell line were measured ($\text{IC}_{50} \sim 2.87 \mu\text{g/ml}$).

1. Introduction

Medicinal inorganic chemistry is an interdisciplinary field of increasing prominence, involving the design of novel therapeutic and diagnostic agents [1–5]. This field gained momentum after the hallmark discovery of cisplatin (*cis*-diamminedichloro platinum(II), $[\text{cis}-(\text{NH}_3)_2\text{PtCl}_2]$) by B. Rosenberg in 1965 and later approved by FDA in 1978 as an antitumor drug for treating solid malignancies by preventing the mitotic division inside the rapidly growing malignant cells [6]. As a consequence, more than 4000 Pt(IV) compounds were tested as potential chemotherapeutic agents for clinical use, such as carboplatin, oxaliplatin and of three others, namely; nedaplatin, lobaplatin and heptaplatin. However, it was noted that a limited number of tumors can be treated with platinum-based anti-cancer drugs and showed a number of undesirable side effects, such as gastrointestinal and hematological toxicity. Additionally, drug-resistance phenomena lowered the impact of the agents [7,8].

The non-platinum antitumor compounds have shown superior chemical and pharmacological properties, including various geometries and coordination numbers,

accessible redox states, good solubility, cellular uptake, kinetically stable, and factors influencing the pharmacological profile different than those of platinum drugs. Among various metal ions, copper is a bio-essential trace element, which plays a vital role in biological processes like electron transfer and endogenous oxidative DNA and tRNA damage associated with aging and cancer. Besides its complexes are preferred molecules for cancer inhibition by chemotherapy [12].

Copper (II) complexes are considered as the most promising alternatives to cisplatin as anticancer drugs. Serum copper levels correlate with tumor incidence and weight, malignant progression, and recurrence in a variety of human cancers; namely Hodgkin's lymphoma, sarcoma, leukemia, and cancer of cervix, breast, liver, and lung as well as brain tumors [13, 14]. Interestingly, the high serum and tissue levels of copper, found in many types of human cancers, support the idea that copper could be used as a potential tumor-specific target [15]. The research design of binding small metal based drug molecules with tRNA at physiological conditions is of a great interest for the biological processes and the development of novel therapeutic agents.

Ribonucleic acid (RNA) has been offered several advantages as attractive target for therapeutic intervention in drug discovery in comparison to DNA due to its unique three dimensional (3D) pockets for specific binding for small ligands [16]. Moreover, RNA molecules have gained remarkable prominence due to the emerging knowledge of their potential and critical roles in many cellular activities and functions [17]. RNA relates to diagnosis and therapy of some diseases originated from viruses such as Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), influenza and flaviviruses [18]. Recently, the interaction of the drug with RNA gained major biological importance for developing RNA-targeted therapeutic agents through the understanding of structural details and thermodynamics of the binding to various RNA structures, toxic and damaging effects etc [19,20]. These studies provide an important rationale for design of new lead anticancer drugs at the active site of action, besides providing the pharmacological profile *in vitro*.

Complex 1 – a dinuclear copper(II) dipeptide piperazine bridged scaffold (Fig. 1) fulfills all the pre-requirements of an efficient chemotherapeutic agent owing to (i) its good aqueous solubility which facilitates its rapid cellular uptake, (ii) high DNA binding propensity also revealed by molecular docking, (iii) high cytotoxic activity, thereby capable of inhibition of DNA synthesis of cancerous cells specifically *via* apoptotic pathways, (iv) specific binding domain for selective recognition and cleavage, (v) unique peptide and piperazine scaffold (recognition element domain) with asymmetric binuclear copper centers, (vi) intramolecular H-bond forming molecular topology [21]. One approach to the development of RNA targeted drug molecules has been to study the interaction of well rely on a deeper understanding

of these binding processes. Therefore, it was thought worthwhile to carry out studies of complex 1 with tRNA and throw insight on therapeutic efficacy of this potential cancer chemotherapeutic drug.

Herein, we report the synthesis and characterization of mixed ligand dinuclear copper(II) complex derived from piperazine and dipeptide (glycyl glycine anion) ligand scaffold as potential chemo-therapeutic drug candidates. The interaction between complex 1 and tRNA was investigated by various spectroscopic, spectrofluorimetric, thermal melting experiments, and molecular docking methods. The results were supplemented with thermodynamic studies utilizing high sensitivity isothermal titration calorimetry.

2. Experimental

2.1. Apparatus and Reagents

Yeast tRNA (Type IX from *Torula* yeast) was purchased from Sigma-Aldrich Corporation and was stored at 4 °C. Its concentration was determined spectrophotometrically using a molar extinction coefficient ($\epsilon \sim 6900 \text{ M}^{-1}\text{cm}^{-1}$ at 260 nm) expressed in terms of nucleotide phosphates [22]. Tris(hydroxymethyl) aminomethane or Tris buffer from Sigma were used as received. Doubly distilled water was used as the solvent throughout the experiments.

Stock solution of the complex ($1 \times 10^{-3} \text{ M}$) was prepared by dissolving the complex in doubly distilled water. NaCl (analytical grade, 1 M) solution was used to maintain the ionic strength of buffer at 0.1 M, pH was adjusted to 7.4 by using HCl. Working standard solution was obtained by appropriate dilution of the stock solution. All reagents were of the best commercial grade and were used without further purification.

Electronic spectra were recorded on UV-1700 PharmaSpec UV-vis spectrophotometer (Shimadzu). Data were reported in $\lambda_{\text{max/nm}}$. Interaction of the complex with tRNA was performed in 0.01 M buffer (pH 7.4). Solutions of RNA in buffer gave a ratio of absorbance at 260 nm and 280 nm of indicating that the sample was free from protein contaminations.

Fluorescence measurements were carried out on a spectrofluorimeter (Hitachi F-2500, Tokyo, Japan) equipped with a 150 W Xenon lamp source and a 1 cm path-length quartz cell.

Circular dichroism (CD) spectra were measured on Jasco J-815-CD spectropolarimeter at room temperature using a 1 cm quartz cuvette. Emission spectra were recorded with a Hitachi F-2500 fluorescence spectrophotometer.

2.2. *In vitro* tRNA Binding Studies

tRNA binding experiments include absorption spectral traces, emission spectroscopy, and CD conformed to the standard methods and practices previously adopted by our laboratory [23, 24]. While measuring the absorption spectra an equal amount of tRNA was added to the compound

solution and the reference solution to eliminate the absorbance of the tRNA itself, and the CD contribution by the tRNA and Tris buffer was subtracted through base line correction.

2.3. Cell Culture

The sw480 cancer cells were obtained from the cell lab of Sun Yat-sen University. All cell lines were cultured in DMEM medium supplemented with fetal bovine serum (10%), penicillin (100 units/ml), and streptomycin as antibiotics (50 units/ml) at 37°C in CO₂ incubator (95% relative humidity, 5% CO₂).

2.4. Cell Viability

Cell viability was determined by measuring the ability of cells to converse MTT to a purple formazan dye. For our purpose, cells were seeded in 96-well tissue culture plates at 2.5×10^3 cells/well for 24 h, and then cells were incubated with medium containing different concentrations of complex 1 for 24 h. After incubation, 20 μ L/well of MTT solution (5 mg/mL PBS) was added and incubated for 4 h. The medium was aspirated and replaced with 150 μ L/well DMSO to dissolve the formazan salt formed. The color intensity of the formazan solution, which reflected the cell growth condition, was measured at 570 nm using a multimode microplate reader (TecanInfinite M200, Austria). Observation of cell morphological change was performed with an Olympus Upright fluorescence microscope (Imager Z1, Carl Zeiss).

2.5. Isothermal Titration Calorimetry (ITC)

Measurements were carried out with a VP-ITC titration calorimeter (MicroCal, Inc, Northampton, MA). Concentrated stock of yeast tRNA was prepared in the target buffer and diluted in the same buffer to achieve desired concentrations. In a typical experiment, complex 1 solution was placed in the calorimeter injection syringe and delivered every 3.0 min to the reaction cell containing the tRNA. Measurements were paired with control experiments for heat of mixing and dilution. Data were analyzed with Levenberg-Marquardt nonlinear regression (MicroCalORIGINPro 8.0). The typical range of variation for enthalpy measurement was $\pm 10\%$.

2.6. Molecular Docking Studies

The rigid molecular docking studies were performed by using HEX 6.3 software [25], is an interactive molecular graphics program for calculating and displaying feasible docking modes of RNA molecule. Structure of the complex 1 was sketched by CHEMSKETCH (<http://www.acdlabs.com>) and convert it into pdb format from mol format by OPENBABEL (<http://www.vcclab.org/lab/babel/>). The crystal structure of the RNA (PDB ID: 6TNA), was retrieved from the RCSB Protein Data Bank (<http://www.rcsb.org/pdb>). Visualization of the docked pose has been done by using CHIMERA (www.cgl.ucsf.edu/chimera) and PyMol (<http://pymol.sourceforge.net/>) molecular

graphics program.

3. Results and Discussion

The synthesis and single crystal X-ray crystallographic studies of a novel metalloprotein complex 1 of the formulation $[\text{Cu}_2(\text{glygly})_2(\text{ppz})(\text{H}_2\text{O})_4] \cdot 2\text{H}_2\text{O}$ (CCDC: 794697), where glygly, an anion of glycyl glycine and ppz, piperazine, were described previously [21].

3.1. Electronic Absorption Studies

Electronic absorption spectroscopy is a reliable tool to examine the binding modes of complexes with tRNA followed by the changes in the absorbance and shift in the wavelength.

Upon addition of tRNA, complex 1 shows an increase in molar absorptivity (hyperchromism; 38%) with a blue shift of 3 nm at 232–278 nm, there was a sharp increase in absorption intensity, hyperchromism (Fig. 2), of the intraligand band at 278 nm, which implicates that complex 1 interacted with tRNA by non-covalent interaction most likely by electrostatic attraction and could be facilitated by hydrogen-bond formation due to the molecular topology of the peptide ligand scaffold of complex 1.

In order to evaluate the binding propensity quantitatively with tRNA, the intrinsic binding constant (K_b) of complex 1 with HSA was calculated using Eq. 1, through a plot of $[tRNA]/\epsilon_a - \epsilon_f$ vs. $[tRNA]$, where $[tRNA]$ represents the concentration of RNA, and ϵ_a , ϵ_f and ϵ_b the apparent extinction coefficient ($A_{\text{obs}}/[\text{complex 1}]$), free and bound complex extinction coefficients, respectively. In plots of $[RNA]/\epsilon_a - \epsilon_f$ vs. $[RNA]$, K_b is given by the ratio of slope to intercept.

$$\frac{[RNA]}{\epsilon_a - \epsilon_f} = \frac{[RNA]}{\epsilon_b - \epsilon_f} + \frac{1}{K_b(\epsilon_a - \epsilon_f)} \quad (1)$$

The intrinsic binding constant K_b values for complex 1 with tRNA were calculated and found to be $4.504 \times 10^4 \text{ M}^{-1}$. Complex 1 has a strong binding affinity for tRNA for both nucleobases and phosphate [26].

3.2. Fluorescence Studies (Ethidium Bromide Displacement Assay)

Fluorescent quenching techniques is commonly used as a 'molecular ruler' in biomolecular structural studies. In the absence of tRNA, no luminescence was observed for the complex 1 in Tris-HCl buffer solution at room temperature, So, the binding of complex 1 with tRNA cannot be directly predicted through the emission spectra.

Binding experiment using ethidium bromide (EB) as a probe. EB (3,8-diamino-5-ethyl-6 phenylphenanthrium bromide), a phenanthridine fluorescence dye, is atypical probe for intercalation, form soluble complexes with tRNA and emits intense fluorescence when intercalated into the base pairs of tRNA [27]. The addition of the complexes to tRNA pretreated with EB ($[tRNA]/[EB]=1$) solution causes

an appreciable reduction in fluorescence intensity due to replacement of EB by the complexes [28]. The complex 1 show a decrease in the emission intensity of EB-tRNA system Fig. 3, which indicated that the complex 1 was bind to tRNA *via* electrostatic interactions releasing EB molecules gradually from the EB-tRNA system.

The quenching efficiency for each complex is evaluated by using Stern–Volmer equation (2) [29]:

$$I_0/I = 1 + K_{SV} \cdot r \quad (2)$$

Where I_0 and I represent the fluorescence intensities in the absence and presence of the complex 1, respectively; r is the concentration ratio of the complex to tRNA, and K_{SV} is used to evaluate the quenching efficiency and is obtained as the slope of I_0/I vs. r ($=[\text{complex 1}]/[\text{tRNA}]$). Stern–Volmer constant, K_{SV} value for the complex 1 was found to be 2.25, indicating the strong affinity of the complex 1 to tRNA.

3.3. Isothermal Titration Calorimetry

Isothermal titration calorimetry (ITC) can provide valuable information above and beyond other analytical methods, due to its high sensitivity for measures the change in enthalpy (ΔH) for almost any bimolecular binding interaction [30]. To further probe the thermodynamics of the interaction of complex 1 with tRNA and dissect the observed binding free energy into enthalpic and entropic components, we have conducted ITC experiments. ITC profile for the binding of complex 1 to tRNA at 30 °C is shown in Fig. 4. Each addition of the complex 1 solution (1.0 mM) to the calorimeter cell, which contained a solution of tRNA (0.1 mM) in 0.2 mM phosphate buffer (pH =7.0) and the reference cell contained doubly distilled water, resulted in the release of heat until the binding was saturated. Upon making an injection of complex 1 heat is generated, these tiny heat effects are detected by semi-conductor thermopiles and the instrument applies thermal power (μ cal/sec) in order to actively compensate for the complex 1 induced heat effect and thus to bring the cells into thermal equilibrium. The data must be corrected for the dilution heats associated with the addition of buffer into tRNA and complex 1 into buffer solution. The area under each peak was integrated, heats of dilution are subtracted and the thermogram for the binding of complex 1 to tRNA has been obtained. The heat released during the binding is related to enthalpy (ΔH) and entropy ($T\Delta S$), free energy (ΔG), and binding affinity (K_b). These thermodynamics parameters are related to each other by the following equations [31]:

$$\Delta G = \Delta H - T\Delta S \quad (3)$$

$$\Delta G = -RT \ln K_b \quad (4)$$

where T is the absolute temperature (303 K) and $R = 8.3151 \text{ J mol}^{-1}\text{K}^{-1}$. According to Eqs. (3) and (4), we calculated $\Delta H = -97.97 \text{ kJ.mole}^{-1}$, $\Delta G = -26.54 \text{ kJ.mole}^{-1}$, $\Delta S = +239.69$, and $K_b = 4.504 \times 10^4 \text{ M}^{-1}$.

The results indicated that the binding of complex 1 to

tRNA is driven by favorable enthalpy along with unfavorable entropy contributions and complex 1 bound to tRNA through groove binding and clearly rule out the intercalative binding of the complex to tRNA. Additionally, the apparent enthalpy increase accompanied a variety of non-covalent molecular interactions, such as specific hydrogen bonds, hydrophobic interactions and van der Waals force [32]. The negative ΔH and positive ΔS values suggest that hydrophobic and hydrogen bond interactions play major roles in the complex 1-tRNA binding reaction and contributed to the stability of the complex.

3.4. Thermal Denaturation Study

The ability of binding complex 1 to enhance the stability of the double-stranded tRNA is generally studied through optical melting studies. When tRNA is heated slowly, the double-stranded tRNA gradually dissociates to single-stranded tRNA, which generates a hyperchromic effect on the absorption spectra ($\lambda_{\text{max}} = 260 \text{ nm}$) of single-stranded tRNA is much higher than in double-stranded tRNA [33]. In general, electrostatic binding along the phosphate backbone of tRNA gives rise to only a small change ($3\text{--}6^\circ\text{C}$) in thermal denaturation temperature, while intercalation leads to a significant rise in thermal denaturation temperature of tRNA due to the stabilization of the Watson–Crick base-paired duplex. Therefore, thermal denaturation experiment of tRNA provides a convenient tool for detecting binding and also assessing relative binding strengths [34]. In the present work, the melting curves of tRNA in the absence and the presence of complex 1 is presented in Fig. 5. The ΔT_m values of tRNA in the presence of complex 1 is 6°C , which is characteristic of non-intercalative binding behavior [35].

3.5. Resonance Energy Transfer Across the tRNA

Fluorescence resonance energy transfer (FRET) is a quantum phenomenon that can be occurs *via* overlapping of emission spectrum of a fluorophore (donor) overlaps with the absorption spectrum of another molecule (acceptor) based on the degree of transition dipole coupling. This process only occurs when the donor and acceptor molecules are sufficiently close to each other, i.e. at a distance of $10\text{--}100 \text{ \AA}$ according to Förster's theory [36]. For each fluorescence platform, an appropriate dye or combination of dyes had to be selected.

EB is known to intercalate into tRNA. Upon intercalation, EB's fluorescence is greatly enhanced. It has been determined that approximately ten molecules of EB are bound to a single tRNA molecule, yet only three molecules of EB are bound in sites that facilitate EB fluorescence. A single strong EB binding site is located adjacent to the sixth base pair of the acceptor stem in tRNA [37]. For use EB as intercalator binding agent into tRNA transferred to complex 1 *via* a Förster type resonance energy transfer when complex 1 simultaneously bound to tRNA.

Under adequate experimental conditions (concentration

and distance), the fluorescence observed when using the excitation wavelength of the donor corresponds to the acceptor because the emission energy of the donor is transferred to the acceptor (Fig. 6). According to Föster resonance energy transfer (FRET), the efficiency of energy transfer (E), as follows, is obeyed according to Foster's theory [38]:

$$E = 1 - \frac{F}{F_0} = \frac{R_0^6}{r^6 + R_0^6} \quad (5)$$

$$r_{DA}^6 = \frac{[R_0^6 (1 - E)]}{E} \quad (6)$$

where F and F_0 are the fluorescence intensities of EB-tRNA in the presence and absence of acceptor (complex 1), r is the distance between acceptor and donor, and R_0 is the critical distance when the transfer efficiency is 50%. The value of R_0 was calculated using the Eq. (7):

$$R_0 = 9.78 \times 10^3 \left(\kappa^2 n^{-4} Q_D J(\lambda) \right)^{1/6} \text{ (in Å)} \quad (7)$$

Where κ^2 is the spatial factor of orientation ($= 2/3$), n is refractive index of the medium ($= 1.33$), Q_D is the fluorescence quantum yield of the donor ($= 0.78$), and $J(\lambda)$ is the overlap integral between donor emission and acceptor absorption defined as:

$$J(\lambda) = \frac{\int_0^\infty F_D(\lambda) \varepsilon(\lambda) \lambda^4 d\lambda}{\int_0^\infty F_D(\lambda) d\lambda} \quad (8)$$

Here $F_D(\lambda)$ is the fluorescence of the donor in the wavelength range λ and $\lambda + d\lambda$, and $\varepsilon(\lambda)$ is the molar extinction coefficient of the acceptor at the wavelength λ . The overlap of the absorption spectrum of the complex 1 with the fluorescence emission spectra of EB-tRNA system is shown in Fig. 7.

The efficiency of energy transfer is calculated by using Eq5 and found to be 97 %. The estimated donor (complex 1)-acceptor (tRNA) distance (r), utilizing Eq 6, is found to be 37 Å (at 25°C). The observation indicates simultaneous binding of the complex 1 to the tRNA at room temperature.

3.6. Circular Dichroism Studies

Circular dichroism (CD) is a powerful and sophisticated tool for identifying conformational changes of tRNA. The observed CD spectrum of tRNA consists of a large positive band at ~ 270 nm due to base stacking interactions, and a weak negative band at ~ 238 nm due to backbone interactions. In general, electrostatic interaction of the complexes with tRNA showed less or no perturbations on the base stacking and helicity bands while intercalator enhances the intensities of both the bands. On incubation of present complex 1 with tRNA, the CD spectrum of tRNA undergoes changes in both positive and negative bands (Fig.

8). In complex 1, after addition of tRNA the CD spectrum shows decrease in positive and in negative bands without shift in the band position. Such results suggest that the CD spectra are closely correlated with tRNA binding affinity [39].

3.7. Cell Viability

The synthetic water soluble complexes were also screened for their anticancer activities as sw480 cell line was the target. The cancer cells were incubated in the presence of increasing concentration of the complex for 24 h, and the anti-proliferation activity was measured according to the procedure described in the experimental part [40]. As shown in Fig. 9. Complex 1 exhibits significant inhibitory effects against the cancer cell line at the range of 0.0–20 $\mu\text{g/ml}$. The IC_{50} value of complex 1 is 2.78 $\mu\text{g/ml}$, which is defined as the concentration of a compound where 50% of the cell growth is inhibited. These results revealed that complex 1 acts as a potential selective anticancer agent with significant GI_{50} values specifically towards sw480 tumor cell line.

3.8. Optical Microscopic Inspection

The optical microscopic images of cells were displayed in Fig. 10. Obviously, the sw480 cancer cells appeared spindle-shaped cell (Fig. 10 a). A large number of cells induces changes in cell shape and morphology and the adherence cell number decreased. The density of cells was evidently decreased with the treatment of 0.625–20 $\mu\text{g/ml}$ complex 1 (Fig. 10 b–f). Furthermore, when the cancer cells were treated with high concentration of complex 1 (20 $\mu\text{g/ml}$), most of the cells were gathered together and suspended in the culture medium. These results indicated that complex 1 could induce the change of cell morphology and inhibit the cancer cells growth in a dose-dependent manner.

3.9. Molecular Docking with tRNA

t-RNAs are versatile molecules with cloverleaf structure that show high degree of folding stabilized by base stacking, base pairing and other tertiary interactions. In order to get more insight into the mode of binding, complex 1 was successively docked with tRNA to determine the preferred binding sites on tRNA. The most extensive region calculated as a binding site for positively charged probes in both tRNAs is located in the deep groove near the junction of the anticodon stem and D stem where, in the crystal structure of tRNA^{Phe} [41]. t-RNA^{Phe} (Fig. 11) is one of the most thoroughly characterized naturally occurring RNA molecule available for such interaction study. In our experiment, rigid molecular docking studies was performed to predict the binding modes of complex 1 with a tRNA (PDB ID:1EHZ), and provide an energetically favorable docked pose that is shown in Fig.12. Complex 1 is in the vicinity of C-49, U-50, G-51, U-59, C-63, and A-64 with the free binding energy of -25.74 kcal/mol. The extra stability is related to the presence of H-bonding between N3 of guanine-51 and

the NH of piperazine and O2 of U59A with amino functionality of dipeptide (glygly) in complex 1. The

results between complex 1 and tRNA were appropriate well with the spectroscopic binding studies.




Fig. 1. (a) Chemical structure and (b) ball and stick model of complex 1, $[Cu_2(glygly)_2(ppz)(H_2O)_4] \cdot 2H_2O$.




Fig. 2. Absorption spectral traces of complex 1 in 5mM TrisHCl/ 50 mMNaCl buffer at pH 7.2 upon addition of tRNA. Inset: Plots of $[tRNA]/\epsilon_t - \epsilon_f (\text{M}^2 \text{ cm})$ vs $[tRNA]$ for the titration of tRNA with complexes ■, experimental data points; full lines, linear fitting of the data. $[Complex\ 1] 6.7 \times 10^{-5} \text{ M}$, $[tRNA] 0.00-3.3 \times 10^{-5} \text{ M}$.




Fig. 3. Emission enhancement spectra of the complex 1 in presence of tRNA (Arrow indicates the change in the intensity upon increasing tRNA concentration).




Fig. 4. Isothermal titrationcalorimetry measurement of complex 1 with tRNA.




Fig. 5. Thermal melting curves of tRNA (●), tRNA + complex 1 (■). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).




Fig. 6. Fluorescence resonance energy transfer (FRET) mechanism.




Fig. 7. Overlap of UV absorption spectra of complex 1 (a) with the fluorescence emission spectra of tRNA (b). The fluorescence emission spectrum of tRNA (1.0×10^{-5} M) and the UV absorption spectrum of complex 1 (1.0×10^{-5} M).




Fig. 8. CD spectra of (—) tRNA alone (—) tRNA in the presence of complex 1 in 5 mM Tris-HCl/50 mM NaCl buffer at 25 °C. [Complex] 1.0×10^{-4} M, [tRNA] 1.0×10^{-4} M.




Fig. 9. Growth inhibition on sw480 cells.




Fig. 10. Inverted microscopic images of sw480 cells incubated separately with only the culture medium as the control (a), 0.625 μM/ml complex 1 (b), 1.25 μM/ml complex 1 (c), 5 μM/ml complex 1 (d), 10 μM/ml complex 1 (e), 20 μM/ml complex 1 (f) for 24 h.




Fig. 11. (a) Docking structure between complex 1 and yeast tRNA (PDB ID: 1EHZ) and (b) cloverleaf model structure of tRNA.




Fig. 12. The interaction mode between complex 1 with tRNA (green colour surface showing hydrogen bond interaction between them.).

4. Conclusion

In this work, we have explored the interaction studies of a new dinuclear copper(II) complex derived from the dipeptide (glycylglycine) and piperazine as a metalloprotein drug to examine their effect on the binding propensity of tRNA and

to elucidate the mechanism of action at the molecular target. The interaction of tRNA with complex 1 was investigated by employing different spectroscopic techniques in accordance with molecular docking techniques. The *in vitro* tRNA binding studies of complex 1 reveal an electrostatic binding mode. The results of optical microscopic inspection and

MTT assay showed that the complex 1 (0.625 –20 µg/ml) could reduced the viability of sw480cells in a dose-dependent manner. The distance between donor (tRNA) and acceptor (complex 1) was obtained according to fluorescence resonance energy transfer (FRET). Additionally, molecular docking studies were performed with molecular target tRNA and in order to validate the experimental results. Therefore, it is concluded that drugs that bind to the tRNA (acceptor stem site) represent an important class of anticancer drugs.

Acknowledgements

Author WMA thanks Ministry of Higher Education & scientific Research, Sana'a, Yemen (Ser. no. 01139/2009) for the sanction of major research grant.

References

- [1] Sanchez-Cano C, Hannon M.J., *Dalton Trans.* (2009) 10702.
- [2] Bruijninx P.C.A., Peter S., *Curr. Opin. Chem. Biol.* 12 (2008) 197.
- [3] Orvig C., Abrams M.J., *Chem Rev.* 99 (1999) 2201.
- [4] Zhang C.X., Lippard S.J., *Curr. Opin. Chem. Biol.* 7 (2003) 481.
- [5] Haas K.L., Franz K.J., *Biology Chem Rev* 109 (2009) 4921.
- [6] Kelland L., *Nature Rev.* 7 (2007) 573.
- [7] Barry P.E., Sadler P.J., *ChemCommun.* 49 (2013) 5106.
- [8] Bokemeyer C., Berger C.C., Hartmann J.T., Kollmannsberger C., Schmoll H.-J., Kuczyk M.A., and Kanz L., *British J Cancer* 77(8) (1998) 1355.
- [9] Thompson K. H., Orvig C., *Dalton Trans.* (2006) 761.
- [10] Via L.D., Magno S.M., Gia O., Marini A.M., Settimo F.D., *J Med. Chem.* 52 (2009) 5429.
- [11] Katsoulakou E., Tiliakos M., Papaefstathiou G., Terzis A., Raptopoulou C., Geromichalos G., *J Inorg. Biochem.* 102 (2008) 1397.
- [12] Ott I., Gust R., *Arch. Pharm. Chem. Life Sci.* 340 (2007) 117.
- [13] Yakuphanoglu F., Sekerci M., *J MolStruct.* 751 (2005) 200.
- [14] Marzano C., Pellei M., Tisato F., Santini C., *Anti-Cancer Agent Med. Chem.* 9 (2009) 185.
- [15] Chen D, Cindy Q.C., Yang H., Dou Q.P., *Cancer Res.* 66(21) (2006) 10425.
- [16] Foloppe N., Matassova N., Aboul-ela F., *Drug Discovery Today* 11 (21/22) (2006) 1019.
- [17] Nelson P., Kiriakidou M., Sharma A., Maniataki E., Mourelatos Z., *Trends Biochem. Sci.* 28 (2003) 534.
- [18] Gallego J., Varani G., *Acc. Chem. Res.* 34 (2001) 836.
- [19] Corey D.R., *J Clin. Invest.* 117 (2007) 3615.
- [20] Paul P., Kumar G.S., *J Hazard Mater* 263 (2013) 735.
- [21] Tabassum S., Al-Asbahy W.M., Afzal M., Arjmand F., Bagchi V., *Dalton Trans.* 41 (2012) 4955.
- [22] Islam M.M., Sinha R., Kumar G.S., *Biophys. Chem.* 125 (2007) 508.
- [23] Reicmann M.E., Rice S.A., Thomas C.A., Doty P., *J. Am. Chem. Soc.* 76 (1954) 3047.
- [24] Wolfe A., Shimer G.H., Meehan T., *Biochemistry* 26 (1987) 6392.
- [25] Mustard D., Ritchie D. W., *Struct. Funct. Bioinf.* 60 (2005) 269.
- [26] Liang X., Zou X., Tana L., Zhu W., *J. Inorg. Biochem.* 104 (2010) 1259.
- [27] Wilson W.D., Ratmeyer L., Zhao M., Strekowski L., Boykin D., *Biochemistry* 32 (1993) 4098.
- [28] Luedtke N.W., Hwang J.S., Nava E., Gut D., Kol M., Tor Y., *Nucleic Acids Res.* 31 (2003) 5732.
- [29] Lakowicz J.R., Weber G., *Biochemistry* 12 (1973) 4161.
- [30] Lo A.T.S., Salam N.K., Hibbs D.E., Rutledge P.J., Todd M.H., *PLoS ONE* 6 (2011) 17446.
- [31] Salim N.N., Feig A.L., *Methods* 47 (2009) 198.
- [32] Pierce M.M., Raman C.S., Nall B.T., *Methods* 19 (1999) 213.
- [33] Onori G., Santucci A., *J. Mol. Liquids* 69 (1996) 161.
- [34] Mei H.-Y., Barton J. K., *Proc. Natl. Acad. Sci. U.S.A.* 85(5) (1988) 1339.
- [35] Giri P., Kumar S.G., *Biochim. Biophys. Acta* 1770 (2007) 1419.
- [36] Nomanbhoy T.K., Schimmel P., *Bioorg. & Med. Chem. Letters* 11 (2001) 1485.
- [37] Xu H., Deng H., Zhang Q.-L., Huang Y, Liu J.-Z., Ji L.-N., *Inorg. Chem. Comm.* 6 (2003) 766.
- [38] Lakowicz J.R., *Principles of Fluorescence Spectroscopy*. Kluwer Academic/Plenum Publishers 2nd ed. (1999) New York.
- [39] Islam M.M., Pandya P., Chowdhury S.R., Kumar S., Kumar G.S., *J. Mol.Struct.* 891 (2008) 498.
- [40] Maree C.F., Janine L.R., Clare M., Terry J., Hong J., Richard J.S., Meredith J.L., and Antony W. B., *J. Cell Science* 117 (2003) 427.
- [41] Agudelo D., Bourassa P., Beauregard M., Bérubé G., Tajmir-Riahi H.-A., *PLOS ONE* 8 (2013) e69248.